|
|
Article: Patients Treated with Merck's Investigational Extended-Release Niacin/Laropiprant (CORDAPTIVE(TM)) Reported Significantly Less Flushing Than Patients Treated with Niaspan(TM) in Phase III Study.
- Article from:
- Business Wire
- Article date:
- March 31, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CHICAGO -- Patients with dyslipidemia treated with CORDAPTIVE[TM] (extended release niacin/laropiprant) reported significantly less flushing and significantly fewer discontinuations due to flushing than patients treated with Niaspan[TM] (Abbott). Niacin is a proven lipid-modifying agent; however, a major barrier to its use is the side effect of flushing. These Phase III study results were presented today at the Scientific Session of the American College of Cardiology in Chicago.
CORDAPTIVE is an investigational lipid-modifying agent in development by Merck & Co., Inc. that combines Merck-developed extended release (ER) niacin with the agent laropiprant, a novel ...